Enanta Pharmaceuticals Inc (ENTA)

[willyw]

SVR12 Rate 97% With 3 DAAs Plus Ribavirin in People on Opioid Replacement

This offers little new, just more of the same, but seems to give the latest statistics on phase 3 results;

http://www.natap.org/2014/IAC/IAC_08.htm

SVR12 Rate 97% With 3 DAAs Plus Ribavirin in People on Opioid Replacement

The 3D regimen has been studied in >2700 patients to date

12 weeks; G-1 patients w/o cirrhosis 96%

12 weeks G-1b patients 99-100% SVR rate in TX naive w/o cirrhosis and WITHOUT RBV

12-24 weeks 3-D and RBV treating compensated cirrhotics =SVR 92-96%

Overall 2% discontinuation rate

I couldn't copy and paste from the document, so slightly different wording (willy)